NASDAQ: CLRBCellectar Biosciences Inc Stock
$3.19+0.16 (+5.28%)
Updated Apr 22, 2024
CLRB Price
$3.19
Fair Value Price
$0.74
Market Cap
$102.91M
52 Week Low
$1.33
52 Week High
$4.45
P/E
-1.03x
P/B
-75.89x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$37.98M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
-9.91
Operating Cash Flow
-$32M
Beta
0.92
Next Earnings
May 2, 2024
Ex-Dividend
N/A
Next Dividend
N/A
CLRB Overview
Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study in patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia and B-cell malignancies; Phase 2B clinical study in r/r multiple myeloma (MM) patients; and Phase I study for various pediatric cancers, r/r head and neck cancers, and R/R MM. The company also develops CLR 1900, a PDC chemotherapeutic program that is in the preclinical development stage to treat solid tumors. It has collaborative PDC programs with Avicenna Oncology GMBH to develop CLR 2000 Series; Orano Med to develop CLR 12120 Series; IntoCell Inc; and LegoChemBio. The company was founded in 2002 and is headquartered in Florham Park, New Jersey.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how CLRB scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
CLRB ($3.19) is overvalued by 332.61% relative to our estimate of its Fair Value price of $0.74 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
CLRB ($3.19) is not significantly undervalued (332.61%) relative to our estimate of its Fair Value price of $0.74 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
CLRB is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more CLRB due diligence checks available for Premium users.
Be the first to know about important CLRB news, forecast changes, insider trades & much more!
CLRB News
Valuation
CLRB fair value
Fair Value of CLRB stock based on Discounted Cash Flow (DCF)
Price
$3.19
Fair Value
$0.74
Overvalued by
332.61%
CLRB ($3.19) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
CLRB ($3.19) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
CLRB is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
CLRB price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-1.03x
Industry
16.21x
Market
41x
CLRB price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-75.89x
Industry
5.82x
CLRB's financial health
Profit margin
Revenue
$0.0
Net Income
-$7.4M
Profit Margin
0%
CLRB's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$12.1M
Liabilities
$13.4M
Debt to equity
-9.91
CLRB's short-term liabilities ($12.94M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
CLRB's short-term assets ($10.45M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
CLRB's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
CLRB's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$9.6M
Investing
-$266.8k
Financing
$441.0k
CLRB's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
CLRB vs Biotech Stocks
Cellectar Biosciences Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.